drugset / Trial / NCT05113355
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Phase 2
Unknown
23 enrolled
Peking Union Medical College Hospital
Harbin Medical University · collabThe First Affiliated Hospital of Xiamen University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety of chidamide combined with sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm.
Timeline
- Start
- 2021-11-17
- Primary completion
- 2022-11-15
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |